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Abstract
Background: Opioid agonist therapy using methadone, an effective treatment of opioid use disorders (OUD) for
people who inject drugs (PWID), is recommended by the World Health Organization as essential to curtail the
growing HIV epidemic. Yet, despite increasing prevalence of OUD and HIV, methadone therapy has not yet been
implemented in Russia. The aim of this modeling study was to estimate the cost-effectiveness of methadone
therapy for Russian adults with a diagnosed OUD.
Methods/Design: We modeled the projected program implementation costs and estimated disability-adjusted life
years (DALYs) averted over a 10-year period, associated with the provision of methadone therapy for a hypothetical,
unreplenished cohort of Russian adults with an OUD (n = 249,000), in comparison to the current therapies at
existing addiction treatment facilities. Our model compared four distinct scenarios of treatment coverage in the
cohort ranging from 3.1 to 55%.
Results: Providing methadone therapy to as few as 3.1% of adults with an OUD amounted to an estimated almost
50,000 DALYs averted over 10 years at a cost of just over USD 17 million. Further expanding service coverage to
55% resulted in an estimated almost 900,000 DALYs averted, at a cost of about USD 308 million.
Conclusion: Our study indicated that implementing opioid agonist therapy with methadone to treat OUD at
existing facilities in Russia is highly cost-effective.
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Background
After the fall of the Soviet Union and formation of the
Russian Federation, smuggling routes of opium were
established from Afghanistan through Russia [18]. These
routes increased the availability of opioid-based drugs in
Russia, mostly heroin, leading to rapid increases in the
number of people who inject drugs (PWID) and thus the
spread of HIV infection. Presently, 1.8% of Russians
inject drugs [30, 45].
With rapid increase in injection drug use in Russia,
the number of new HIV infections grew 5.3% on average
in the past 10 years, making it one of the highest HIV
infection rates in the world [39, 45, 47]. Moreover,
substance use, HIV, and tuberculosis frequently co-occur
in the country [23]. The HIV epidemic in Russia is
primarily driven by injection drug use; up to 70% of HIV
positive Russians have been infected through injection
drug use [1, 9]. This is seven times the world average of
10% [29]. Based on the latest report from the Russian
Ministry of Health, 540,000 PWID currently live in
Russia, and 40,500 are hospitalized annually for opioid
use disorder (OUD) based on International Statistical
Classification of Diseases and Related Health Problems
(ICD) 10 standards [20]. In 2015, a mere 14% of HIV-
positive Russians received antiretroviral therapy (ART),
placing the country among the lowest in the world with
regard to ART rates among those infected with HIV
[45]. Among PWID, access to HIV care is even dispro-
portionately lower, but improving narcology services is
an opportunity, since appropriate addiction care has
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shown to improve engagement in HIV treatment in
other parts of the world [40, 47].
One of the major factors contributing to the growing
HIV epidemic in Russia is the lack of evidence-based
prevention and treatment programs for both HIV and
substance use directed to populations at risk, such as
PWID. Because opioid agonist therapy (OAT) using
methadone or buprenorphine is not legal in Russia
and funding for effective, legal programs such as nee-
dle and syringe exchanges is limited, it is assumed
that many preventable HIV infections occur each year
in Russia [26, 27, 32].
The standard of care at Russian inpatient narcology
hospitals consists of diagnostic procedures, detoxifica-
tion, and rehabilitation. Detoxification typically occurs
within the first week of hospitalization. The process,
which occurs mostly at inpatient setting, typically uti-
lizes the following medications for opioid withdrawal
therapy: antidepressants, antipsychotics, anticonvulsants,
non-opiate analgesics, adrenergic, and alfa 2 agonist.
The only available medication in Russia that has been
shown to be effective at preventing opioid use relapse is
the opiate antagonist naltrexone, which is generally
only administrated upon discharge from inpatient care
[21, 22, 32]. During inpatient hospitalization, patients
receive drug counselling and treatment for comorbid
psychiatric conditions, but integration to other treat-
ment modalities such as HIV care is limited [14, 19].
PWID are encouraged to receive monthly outpatient
care where they could receive psychotherapy and re-
ferral for treatment of comorbid conditions. However,
linking and retaining patients in care is challenging, as
narcology hospitals are limited in their capability to pro-
vide evidence-based pharmacological treatment, and their
patients are subject to immense stigmatization [26].
OAT using methadone or the partial agonist buprenor-
phine is regarded to be the most effective treatment for
opioid use disorders and beneficial as a harm reduction
program to reduce HIV risks [25, 31]. The World Health
Organization (WHO) has endorsed OAT and harm
reduction. Methadone, included in its list of essential
medications, was already used by 59 countries world-
wide in 2009 [48]. In addition to being an effective
therapy for OUD, methadone has also been shown to
provide advantageous economic value [34]. PWID are
administered methadone treatment to reduce or elimin-
ate cravings and withdrawal symptoms of illicit opiates.
Methadone acts as a full agonist of mu (μ) receptors in
neurons acting via inhibitory G protein resulting in pre-
synaptic inhibition of neurotransmitters [46]. Methadone
is a full agonist and 3 times more potent than morphine
with a 1–3 day half-life, which makes it suitable for use
in harm reduction programs (see graph 1 for list of
desirable indirect effects of OAT).
Despite the multiple benefits associated with OAT, it
has not yet been accepted in the Russian health system.
Determining the potential benefits of an OAT program
in Russia is relevant, as opioid use disorders and HIV
infections associated with drug use are likely to continue
to increase until effective OUD treatment programs are
introduced [3, 5].
The aim of this paper is to estimate the cost-
effectiveness attributable to the hypothetical introduction




We modeled the cost and disability adjusted life years
(DALYs) averted associated with the provision of metha-
done therapy for a hypothetical, unreplenished cohort of
Russian adults with an OUD, relative to the current
system where OAT is legally banned. According to a
2016 Russian Ministry of Health report, the number of
opioid users who met OUD criteria was approximately
249,000 nationwide, most of whom are injection drug
users [20]. As recommended in the World Health
Organization’s Guide to Cost-Effectiveness Analysis [10],
cost (converted to 2015 U.S. Dollars) and outcomes
(DALYs) were modeled over a 10-year horizon. Cost and
DALYs occurring beyond 1 year were discounted at the
recommended yearly rate of 3% to account for time
preference [10].
Although partial agonists such as buprenorphine are
also used effectively to treat opioid dependence world-
wide, our analyses focus on methadone only; however,
we believe that all options should be explored for
patients. Methadone therapy (MT) has typically been
shown to be the most economically viable option, with
rates of effectiveness that are at least as good as those
for buprenorphine maintenance therapy, at a lower cost
[35]. Thus, methadone therapy would be a logical choice
for implementing a large-scale OAT program. We inter-
preted our results in the context of the cost-effectiveness
thresholds recommended by the World Health Organi-
zation’s Choosing Interventions that are Cost–Effective
project (WHO-CHOICE). They state that interventions
capable of averting one DALY for < 3x the per-capita
gross domestic product (GDP) should be considered
“cost-effective”, while those capable of doing so at a cost
below the per-capita GDP should be considered “highly
cost-effective” [49].
Methadone therapy for OUD: initiation and retention
We considered several scenarios for implementing a
national methadone therapy program. Similar to Alistar
et al. [2], we used a “low” scenario where treatment
would be available for 3.1%, a “moderate” scenario with
Idrisov et al. Substance Abuse Treatment, Prevention, and Policy  (2017) 12:4 Page 2 of 6
slots for 12.5%, and a “high” scenario with slots available
for 25%. We also considered a scenario with slots avail-
able for 55% of the adult OUD population, which was
based on the maximum coverage in Vietnam following
the government’s decision to expand OAT programs
upon successful completion of their pilot program [36].
Methadone therapy retention rates were also based off
findings from the first Vietnamese MT cohort, where the
response rate was 89.9% after 9 months [42].
Effectiveness measurement
Effectiveness of the proposed rate of methadone therapy
coverage was measured by calculating DALYs averted.
The DALY is a global measure of disease burden with
possible scores ranging from 0 (no disability/ impact) to
1 (one year of “entirely healthy life” lost). Similar to the
quality-adjusted life-year (QALY), the DALY is a
generalizable measure of effectiveness, which permits
comparisons across diseases and interventions. DALYs
are calculated by adding Years of Life Lost (YLL) and
Years Lost due to Disability (YLD) [10]. YLL were calcu-
lated by multiplying the number of deaths in a year by
the average number of years of life lost due to opioid
use. For YLL, we used the all-cause mortality rates
estimated by Chang et al. [7], both for patients who used
heroin and were in opioid substitution therapy, 15.5 per
1000 person years, and those who were not in opioid
substitution therapy, 23.9 per 1000 person years. We
then multiplied these figures by the respective average
number of years of life lost, which were 10.6 for patients
who used heroin and were on methadone therapy and
18.6 for those who were not [7]. To calculate YLD, we
first estimated the prevalent number of individuals with
an OUD and a comorbid HIV infection, and the number
with an OUD and comorbid HIV and tuberculosis (TB)
infections, as well as the number with an OUD who did
not have these comorbidities. Prevalence of co-occurring
OUD and HIV was obtained from a systematic review
performed by Jolley and colleagues [17], who found that
approximately 30% of Russian PWID have HIV. The
number of individuals with comorbid OUD, HIV, and
TB was estimated by averaging prevalence rates from
three studies which found TB rates of 17%, [13] 18.2%
[11] and 20.3% [33] among HIV infected patients, which
yielded a final estimate of 18.5%. The estimated number
of prevalent cases for each disorder/disease state was
then multiplied by the associated disability weight ob-
tained from Salomon et al. [38], with disability weights
for comorbid states calculated using the multiplicative
approach [15].
Cost measures
The per-person treatment costs were taken from Tran
et al. [43], who estimated the average cost of running
Vietnam’s methadone therapy program from the
perspective of their national healthcare system to be
$278 [2015 USD]. We assumed costs in the Russian
Federation, likewise an (upper) middle-income country,
to be similar, if not lower once implemented.
Results
Table 1 displays the estimated present-value costs and
DALYs averted for each of the four scenarios. The “low”
scenario of supplying OAT to 3.1% of adults with an
OUD resulted in a present value of 49,739 DALYs
averted at a total cost of $17,068,524 over the modeled
10-year horizon. Expanding the number of opioid
substitution slots to 12.5% of the OUD population re-
sulted in present value estimates of 201,234 DALYS
averted at a cost of $69,051,186 over 10 years. The
scenarios where slots are available to 25% or 55% of the
OUD population resulted in present value estimates of
404,265 and 898,958 DALYs averted, respectively, at
costs of $138,707,623 and $308,382,234, respectively.
Discussion
Unfortunately, the care for patients with an OUD in
Russian narcology hospitals is associated with low suc-
cessful treatment outcomes and follow up rates [24, 32].
To our knowledge, this study is the first to estimate the
effectiveness of implementing an evidence-based form of
OAT in Russia, as well as the associated costs. Results
indicate that a national methadone program could be
implemented in Russia at a cost-per-DALY-averted of
$343 [2015 USD]. Given that Russia’s 2015 per-capita
GDP was $9057 [41], these estimates are well below
the cost-effectiveness thresholds recommended by the
WHO-CHOICE framework, indicating that imple-
menting an OAT program in Russia would be “highly
cost-effective”.
Although OAT is not yet available in Russia, in our
opinion the infrastructure partially exists to implement
such programs [50, 51] and unlike most countries facing
a similar challenge of HIV and substance use epidemics,
Russia has a sufficient number of qualified health care
cadres and institutions [37]. Free healthcare in Russia is
a constitutional right; however, patients may only use
their mandatory insurance coverage at public hospitals
since private-based hospitals rarely contract with the
Mandatory Health Insurance Fund (MHIF). Russian
citizens contribute to MHIF by way of mandatory pay-
ments though general taxation and payroll contributions.
The model of service delivery in Russia is built as a
multi-level system with different networks of healthcare
facilities organized by specialty (e.g. primary care, HIV,
TB, addiction) and geographical location [37]. The levels
consist of rural/small-district outpatient facilities, central
rural/municipal hospitals, regional hospitals and federal
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hospitals [8, 37]. Substance use disorder is treated at
specialized narcology hospitals that also consist of
district level outpatient facilities and larger inpatient
narcology hospitals. Given that these facilities are already
built and functioning, start-up costs for an OAT pro-
gram would likely be minimal. Modalities of provision
could be derived from former Soviet countries with simi-
lar health system infrastructures, such as Ukraine, where
OAT exists and has been demonstrated to improve care
quality and quality of life among HIV infected PWID,
especially if integrated with HIV care [4, 28].
There are several limitations to our study. First, we
used a prevalence-based model, as opposed to a state-
based model, which allows individuals to transition from
one health state to another over the modeled time
period, according to estimated transition probabilities.
Furthermore, we were unable to estimate the number of
individuals with HIV who were on ART, which limits
our ability to incorporate the benefits of increased use of
ART associated with adherence to OAT [44]. When
calculating DALYs, we used a conservative approach and
calculated YLDs using the disability weight of 0.221
associated with “HIV: symptomatic, pre-AIDS” versus
the 0.547 weight associated with “AIDS: not receiving
ART”. Increased ART adherence has a positive impact
on the number of DALYs averted [6, 12]. This is espe-
cially relevant in locations with high rates of HIV among
people who use drugs and low ART coverage, such as in
St. Petersburg where 43% of PWID are HIV positive
with low treatment continuum [16]. Future studies on
effectiveness of an OAT program in Russia should also
focus on data validity. For example, many of the preva-
lence rates built into the model, as well as the estimated
cost of implementing the methadone program, were
derived from studies performed in other countries due
to a lack of such information in Russia. Finally, like any
model, our study does not entirely reflect all costs and
benefits to society that may be associated with the
implementation of an OAT program. That is, prior stud-
ies have shown evidence of cost-offsets associated with
effective OAT, resulting from reduced use of high-cost
healthcare services (e.g., the emergency department) and
non-health related outcomes such as reduced criminal
activity [35].
Conclusion
This study suggests that implementing a methadone
therapy program in Russia would be highly cost-effective
due to its effectiveness in averting DALYs among people
who inject drugs. Russia’s robust health workforce and
its constitutionally assured right to health provide a
formidable implementation framework for updating the
Russian addiction treatment and rehabilitation standards
to include international, evidence-based addiction treat-
ment with opioid agonist medication. This will reduce
the burden of disease related to substance use and asso-
ciated conditions such as HIV and TB. By reconsidering
its position on opioid agonist therapy, Russia could
create substantial progress in the country’s fight against
the burden of, OUD, HIV and other drug-related dis-
eases, as well as the human tragedies behind them.
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Table 1 Predicted costs and effectiveness outcomes
MT supplied to 3.1%
of OUD population
MT supplied to 12.5%
of OUD population
MT supplied to 25%
of OUD population












1 6,562 2,145,882 26,458 8,652,750 52,916 17,305,500 116,415 38,072,100 327
2 6,148 2,034,130 24,810 8,208,772 49,674 16,435,185 109,568 36,250,553 331
3 5,759 1,928,198 23,262 7,787,574 46,626 15,608,638 103,115 34,516,158 335
4 5,395 1,827,783 21,808 7,387,988 43,759 14,823,660 97,034 32,864,744 339
5 5,053 1,732,597 20,441 7,008,905 41,064 14,078,160 91,304 31,292,342 343
6 4,731 1,642,368 19,158 6,649,274 38,531 13,370,151 85,905 29,795,170 347
7 4,430 1,556,838 17,953 6,308,095 36,149 12,697,749 80,819 28,369,630 351
8 4,147 1,475,762 16,822 5,984,422 33,910 12,059,164 76,027 27,012,295 356
9 3,882 1,398,908 15,759 5,677,358 31,806 11,452,693 71,512 25,719,901 360
10 3,633 1,326,057 14,762 5,386,049 29,829 10,876,723 67,260 24,489,341 365
Present value 49,739 17,068,524 201,234 69,051,186 404,265 138,707,623 898,958 308,382,234 343
aDiscounted at 3% after year 1; b2015 US Dollars
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